title: Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma.
abstract: Intravesical application of bacillus Calmette-Guérin (BCG) is highly active against recurrences of superficial urothelial bladder carcinoma. In an attempt to monitor the immunological effects of this therapy, we analyzed the urine of patients following the sixth intravessical instillation, to show the presence of the monokines TNF and IL 1 and the lymphokine IL 2. Within 24 hours following the instillation, all (n = 10) patients exhibited a strong increase in urinary cytokine secretion, which was significantly different from the control group (n = 10), with respect to TNF L929 biological assay (P less than 0.01), TNF sandwich-ELISA (P less than 0.01), IL 2 CTL 6 biological assay (P less than 0.05), IL 2 sandwich-ELISA (P less than 0.005), and IL 1 sandwich-ELISA (P less than 0.05), but not to the IL 1 fibroblast biological assay. The maximum urinary secretion varied between individual patients and different cytokines, but was generally found within 2 to 8 hr after the instillation. A persistent high urinary activity was demonstrated in BCG-treated patients for IL 2 in sandwich-ELISA. These results reflect the local inflammatory response to BCG and suggest an immunomodulatory mode of action against urothelial carcinoma cells. Elucidation of the possible role of each urinary cytokine against this cancer warrants further investigations.
authors.affiliation: Department of Urology, Medical University of Lübeck, Borstel, FRG.
authors.forename: A
authors.initials: A
authors.lastname: Böhle
authors.forename: C
authors.initials: C
authors.lastname: Nowc
authors.forename: A J
authors.initials: AJ
authors.lastname: Ulmer
authors.forename: J
authors.initials: J
authors.lastname: Musehold
authors.forename: J
authors.initials: J
authors.lastname: Gerdes
authors.forename: A G
authors.initials: AG
authors.lastname: Hofstetter
authors.forename: H D
authors.initials: HD
authors.lastname: Flad
mesh_terms: D001500:BCG Vaccine / Q000627:therapeutic use*; D002277:Carcinoma / Q000628:therapy* / Q000652:urine; D006801:Humans; D007167:Immunotherapy; D007375:Interleukin-1 / Q000652:urine; D007376:Interleukin-2 / Q000652:urine; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000652:urine; D001749:Urinary Bladder Neoplasms / Q000628:therapy* / Q000652:urine
chemical_list: D001500:BCG Vaccine; D007375:Interleukin-1; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha